



2021 EU-wide Transparency Exercise

Bank Name	Ibercaja Banco, S.A.
LEI Code	549300OLBL49CW8CT155
Country Code	ES

The information on Collateral valuation - loans and advances applies only to banks meeting at least one of the criteria for significance and having a ratio of non-performing loans and advances divided by total loans and advances (excluding loans and advances classified as held for sale, cash balances at central banks and other demand deposits) of 5% or above, therefore this bank is not required to report it to the EBA.

2021 EU-wide Transparency Exercise

Key Metrics

Ibercaja Banco, S.A.

(min EUR, %)	As of 30/09/2020	As of 31/12/2020	As of 31/03/2021	As of 30/06/2021	COREP CODE	REGULATION
Available capital (amounts)						
Common Equity Tier 1 (CET1) capital - transitional period	2,470	2,485	2,470	2,480	C 01.00 (r020,c010)	Article 50 of CRR
Common Equity Tier 1 (CET1) capital - transitional period - as if IFRS 9 or analogous ECLs transitional arrangements had not been applied	2,361	2,366	2,374	2,386	C 01.00 (r020,c010) - C 05.01 (r440,c010)	Article 50 of CRR
Tier 1 capital - transitional period	2,820	2,835	2,820	2,830	C 01.00 (r015,c010)	Article 25 of CRR
Tier 1 capital as if IFRS 9 or analogous ECLs transitional arrangements had not been applied - transitional definition	2,711	2,716	2,724	2,736	C 01.00 (r015,c010) - C 05.01 (r440,c010) - C 05.01 (r440,c020)	Article 25 of CRR
Total capital - transitional period	3,320	3,335	3,320	3,330	C 01.00 (r010,c010)	Articles 4(118) and 72 of CRR
Total capital - transitional period - as if IFRS 9 or analogous ECLs transitional arrangements had not been applied	3,211	3,216	3,224	3,236	C 01.00 (r010,c010) - C 05.01 (r440,c010) - C 05.01 (r440,c020) - C 05.01 (r440,c030)	Articles 4(118) and 72 of CRR
Risk exposure amounts						
Total risk exposure amount	18,309	18,248	18,503	18,364	C 02.00 (r010,c010)	Articles 92(3), 95, 96 and 98 of CRR
Total risk exposure amount as if IFRS 9 or analogous ECLs transitional arrangements had not been applied	18,255	18,191	18,457	18,320	C 02.00 (r010,c010) - C 05.01 (r440,c040)	Articles 92(3), 95, 96 and 98 of CRR
Capital ratios						
Common Equity Tier 1 (as a percentage of risk exposure amount) - transitional definition	13.49%	13.62%	13.35%	13.50%	CA3 {1}	-
Common Equity Tier 1 (as a percentage of risk exposure amount) - transitional definition - as if IFRS 9 or analogous ECLs transitional arrangements had not been applied	12.93%	13.00%	12.86%	13.03%	(C 01.00 (r020,c010) - C 05.01 (r440,c010)) / (C 02.00 (r010,c010) - C 05.01 (r440,c040))	-
Tier 1 (as a percentage of risk exposure amount) - transitional definition	15.40%	15.53%	15.24%	15.41%	CA3 {3}	-
Tier 1 (as a percentage of risk exposure amount) as if IFRS 9 or analogous ECLs transitional arrangements had not been applied	14.85%	14.93%	14.76%	14.94%	(C 01.00 (r015,c010) - C 05.01 (r440,c010) - C 05.01 (r440,c020)) / (C 02.00 (r010,c010) - C 05.01 (r440,c040))	-
Total capital (as a percentage of risk exposure amount) - transitional definition	18.13%	18.27%	17.94%	18.13%	CA3 {5}	-
Total capital (as a percentage of risk exposure amount) as if IFRS 9 or analogous ECLs transitional arrangements had not been applied	17.59%	17.68%	17.46%	17.67%	(C 01.00 (r010,c010) - C 05.01 (r440,c010) - C 05.01 (r440,c020) - C 05.01 (r440,c030) / (C 02.00 (r010,c010) - C 05.01 (r440,c040))	-
Leverage ratios						
Leverage ratio total exposure measure - using a transitional definition of Tier 1 capital	46,444	45,296	45,701	46,983	C 47.00 (r300,c010)	Article 429 of the CRR; Delegated Regulation (EU) 2015/62 of 10 October 2014 amending CRR
Leverage ratio - using a transitional definition of Tier 1 capital	6.07%	6.26%	6.17%	6.02%	C 47.00 (r340,c010)	Article 429 of the CRR; Delegated Regulation (EU) 2015/62 of 10 October 2014 amending CRR

2021 EU-wide Transparency Exercise

Leverage ratio

Ibercaja Banco, S.A.

(mln EUR, %)		As of 30/09/2020	As of 31/12/2020	As of 31/03/2021	As of 30/06/2021	COREP CODE	REGULATION
A.1	Tier 1 capital - transitional definition	2,820	2,835	2,820	2,830	C 47.00 (r320,c010)	Article 429 of the CRR; Delegated Regulation (EU) 2015/62 of 10 October 2014 amending CRR
A.2	Tier 1 capital - fully phased-in definition	2,633	2,640	2,668	2,682	C 47.00 (r310,c010)	
B.1	Total leverage ratio exposures - using a transitional definition of Tier 1 capital	46,444	45,296	45,701	46,983	C 47.00 (r300,c010)	
B.2	Total leverage ratio exposures - using a fully phased-in definition of Tier 1 capital	46,257	45,101	45,549	46,835	C 47.00 (r290,c010)	
C.1	Leverage ratio - using a transitional definition of Tier 1 capital	6.1%	6.3%	6.2%	6.0%	[A.1]/[B.1]	
C.2	Leverage ratio - using a fully phased-in definition of Tier 1 capital	5.7%	5.9%	5.9%	5.7%	[A.2]/[B.2]	

(mto EUR, %)			As of 30/09/2020	As of 31/12/2020	As of 31/03/2021	As of 30/06/2021	COREP CODE	REGULATION
OWN FUNDS Transitional period	A	OWN FUNDS	3,320	3,335	3,320	3,330	C 01.00 (y01c,y03)	Articles 4(18) and 72 of CRR
	A.1	COMMON EQUITY TIER 1 CAPITAL (net of deductions and after applying transitional adjustments)	2,470	2,485	2,470	2,480	C 01.00 (y02c,y03)	Article 50 of CRR
	A.1.1	Capital instruments eligible as CET1 Capital (including share premium and net own capital instruments)	214	214	214	214	C 01.00 (y02c,y03)	Articles 26(1) points (a) and (b), 27 to 29, 36(1) point (f) and 41 of CRR
	A.1.2	Retained earnings	659	643	667	667	C 01.00 (y13c,y03)	Articles 26(1) point (c), 26(2) and 36 (1) points (a) and (f) of CRR
	A.1.3	Accumulated other comprehensive income	63	58	39	35	C 01.00 (y18c,y03)	Articles 4(20), 26(1) point (e) and 36 (1) point (f) of CRR
	A.1.4	Other Reserves	1,942	1,950	1,951	1,953	C 01.00 (y20c,y03)	Articles 4(17) and 26(1) point (a) of CRR
	A.1.5	Funds for general banking risk	0	0	0	0	C 01.00 (y21c,y03)	Articles 4(12), 26(1) point (f) and 36 (1) point (f) of CRR
	A.1.6	Minority interest given recognition in CET1 capital	0	0	0	0	C 01.00 (y23c,y03)	Article 84 of CRR
	A.1.7	Adjustments to CET1 due to prudential filters	-20	-10	6	5	C 01.00 (y25c,y03)	Articles 32 to 35 of and 36 (1) point (f) of CRR
	A.1.8	(-) Intangible assets (including Goodwill)	-221	-220	-223	-202	C 01.00 (y30c,y03) + C 01.00 (y34c,y03)	Articles 4(13), 36(1) point (b) and 37 of CRR, Articles 4(15), 36(1) point (b) and 37 point (d) of CRR
	A.1.9	(-) DTAs that rely on future profitability and do not arise from temporary differences net of associated DT/L	-354	-344	-335	-334	C 01.00 (y37c,y03)	Articles 36(1) point (c) and 38 of CRR
	A.1.10	(-) IRR shortfalls of credit risk adjustments to expected losses	0	0	0	0	C 01.00 (y38c,y03)	Articles 36(1) point (d), 40 and 150 of CRR
	A.1.11	(-) Defined benefit pension fund assets	0	0	0	0	C 01.00 (y39c,y03)	Articles 4(20), 36(1) point (a) and 41 of CRR
	A.1.12	(-) Reciprocal cross holdings in CET1 Capital	0	0	0	0	C 01.00 (y40c,y03)	Articles 4(12), 36(1) point (g) and 44 of CRR
	A.1.13	(-) Excess deduction from AT1 items over AT1 Capital	0	0	0	0	C 01.00 (y40c,y03)	Article 36(1) point (f) of CRR
	A.1.14	(-) Deductions related to assets which can alternatively be subject to a 1.250% risk weight	0	0	0	0	C 01.00 (y40c,y03) + C 01.00 (y40c,y03) + C 01.00 (y47c,y03) + C 01.00 (y47c,y03)	Articles 4(36), 36(1) point (d) (i) and 88 to 91 of CRR, Articles 36(1) point (d) (i), 24(1) point (b), 24(1) point (b) and 258 of CRR, Articles 36(1) point (i) (b) and 276(1) of CRR, Articles 36(1) point (i) (v) and 153(3) of CRR and Articles 36(1) point (i) (v) and 153(6) of CRR
	A.1.14.1	Of which: from securitisation positions (-)	0	0	0	0	C 01.00 (y40c,y03)	Articles 36(1) point (i) (i), 24(1) point (b), 24(1) point (b) and 258 of CRR
	A.1.15	(-) Holdings of CET1 capital instruments of financial sector entities where the institution does not have a significant investment	0	0	0	0	C 01.00 (y40c,y03)	Articles 4(27), 36(1) point (j), 43 to 46, 48 (2) and (3), and 79 of CRR
	A.1.16	(-) Deductible DTAs that rely on future profitability and arise from temporary differences	0	0	0	0	C 01.00 (y40c,y03)	Articles 36(1) point (c) and 38, Articles 48(1) point (a) and 48(2) of CRR
	A.1.17	(-) Holdings of CET1 capital instruments of financial sector entities where the institution has a significant investment	0	0	0	0	C 01.00 (y40c,y03)	Articles 4(27), 36(1) point (j), 43, 45, 47, 48(1) point (b), 48(1) to (3) and 79 of CRR
	A.1.18	(-) Amount exceeding the 17.65% threshold	0	0	0	0	C 01.00 (y51c,y03)	Article 48 of CRR
	A.1.18A	(-) Insufficient coverage for non-performing exposures				-2	C 01.00 (y51c,y03)	Article 36(1) point (m) and Article 47c CRR
	A.1.18B	(-) Minimum value commitment shortfalls				0	C 01.00 (y54c,y03)	Article 36(1) point (n) and Article 133(2) CRR
	A.1.18C	(-) Other foreseeable tax charges				0	C 01.00 (y55c,y03)	Article 36(1) point (o) CRR
	A.1.19	(-) Additional deductions of CET1 Capital due to Article 3 CRR	0	0	0	-25	C 01.00 (y52c,y03)	Article 3 CRR
	A.1.20	CET1 capital elements or deductions - other	0	0	0	0	C 01.00 (y52c,y03)	-
	A.1.21	Transitional adjustments	187	195	152	148	GA (1.1.1.6 + 1.1.1.8 + 1.1.1.26)	-
	A.1.21.1	Transitional adjustments due to grandfathered CET1 Capital instruments (+/-)	0	0	0	0	C 01.00 (y22c,y03)	Articles 48(1) to (3), and 484 to 487 of CRR
	A.1.21.2	Transitional adjustments due to additional minority interests (+/-)	0	0	0	0	C 01.00 (y30c,y03)	Articles 479 and 480 of CRR
	A.1.21.3	Other transitional adjustments to CET1 Capital (+/-)	187	195	152	148	C 01.00 (y52c,y03)	Articles 469 to 472, 478 and 481 of CRR
	A.2	ADDITIONAL TIER 1 CAPITAL (net of deductions and after transitional adjustments)	350	350	350	350	C 01.00 (y53c,y03)	Article 61 of CRR
	A.2.1	Additional Tier 1 Capital instruments	350	350	350	350	C 01.00 (y54c,y03) + C 01.00 (y67c,y03)	
	A.2.2	(-) Excess deduction from T2 items over T2 capital	0	0	0	0	C 01.00 (y72c,y03)	
A.2.3	Other Additional Tier 1 Capital components and deductions	0	0	0	0	C 01.00 (y68c,y03) + C 01.00 (y70c,y03) + C 01.00 (y71a,y03) + C 01.00 (y70c,y03) + C 01.00 (y71a,y03) + C 01.00 (y71a,y03)		
A.2.4	Additional Tier 1 transitional adjustments	0	0	0	0	C 01.00 (y68c,y03) + C 01.00 (y68c,y03) + C 01.00 (y72c,y03)		
A.3	TIER 1 CAPITAL (net of deductions and after transitional adjustments)	2,820	2,835	2,820	2,830	C 01.00 (y1c,y03)	Article 25 of CRR	
A.4	TIER 2 CAPITAL (net of deductions and after transitional adjustments)	500	500	500	500	C 01.00 (y70c,y03)	Article 71 of CRR	
A.4.1	Tier 2 Capital instruments	500	500	500	500	C 01.00 (y70c,y03) + C 01.00 (y69c,y03)		
A.4.2	Other Tier 2 Capital components and deductions	0	0	0	0	C 01.00 (y69c,y03) + C 01.00 (y70c,y03) + C 01.00 (y71a,y03) + C 01.00 (y70c,y03) + C 01.00 (y71a,y03) + C 01.00 (y71a,y03)		
A.4.3	Tier 2 transitional adjustments	0	0	0	0	C 01.00 (y68c,y03) + C 01.00 (y70c,y03) + C 01.00 (y70c,y03)		
B	TOTAL RISK EXPOSURE AMOUNT	18,309	18,248	18,503	18,364	C 02.00 (y01c,y03)	Articles 93(2), 95, 96 and 98 of CRR	
B.1	Of which: Transitional adjustments included	54	57	46	45	C 01.00 (y01c,y04)		
C.1	COMMON EQUITY TIER 1 CAPITAL RATIO (transitional period)	13.49%	13.62%	13.35%	13.50%	CA3 (1)	-	
C.2	TIER 1 CAPITAL RATIO (transitional period)	15.40%	15.53%	15.24%	15.41%	CA3 (3)	-	
C.3	TOTAL CAPITAL RATIO (transitional period)	18.13%	18.27%	17.94%	18.13%	CA3 (5)	-	
CET1 Capital Fully loaded	D	COMMON EQUITY TIER 1 CAPITAL (fully loaded)	2,283	2,290	2,318	2,332	[A1+A.1.13+A.1.21+MIN(A.2+A.1.13+A.2.3+A.2.4+MIN(A.4+A.2.3+A.4.3),0)]	-
CET1 RATIO (%) Fully loaded?	E	COMMON EQUITY TIER 1 CAPITAL RATIO (fully loaded)	12.51%	12.59%	12.56%	12.73%	[D1]/[B+6.1]	-
Memo Items	F	Adjustments to CET1 due to IFRS 9 transitional arrangements	109	119	97	94	C 05.01 (y40c,y03)	
	F	Adjustments to AT1 due to IFRS 9 transitional arrangements	0	0	0	0	C 05.01 (y40c,y03)	
	F	Adjustments to T2 due to IFRS 9 transitional arrangements	0	0	0	0	C 05.01 (y40c,y03)	
	F	Adjustments included in RWAs due to IFRS 9 transitional arrangements	54	57	46	45	C 05.01 (y40c,y04)	

(1) The fully loaded CET1 ratio is an estimate calculated based on bank's supervisory reporting. Therefore, any capital instruments that are not eligible from a regulatory point of view at the reporting date are not taken into account in this calculation. Fully loaded CET1 capital ratio estimation is based on the formulae stated in column "COREP CODE" – please note that this might lead to differences to fully loaded CET1 capital ratios published by the participating banks e.o. in their Pillar 3 disclosures.

2021 EU-wide Transparency Exercise

Overview of Risk exposure amounts

Ibercaja Banco, S.A.

(mln EUR, %)	RWAs				COREP CODE
	As of 30/09/2020	As of 31/12/2020	As of 31/03/2021	As of 30/06/2021	
Credit risk (excluding CCR and Securitisations) ¹	16,898	16,858	17,113	16,943	C 02.00 (r040, c010) - [C 07.00 (r090, c220, s001) + C 07.00 (r110, c220, s001) + C 07.00 (r130, c220, s001) + C 08.01 (r040, c260, s001) + C 08.01 (r050, c260, s001) + C 08.01 (r060, c260, s001) + C 08.01 (r040, c260, s002) + C 08.01 (r050, c260, s002) + C 08.01 (r060, c260, s002)] - [C 02.00 (R470, c010)] - C 02.00 (R460, c010)]
Of which the standardised approach	16,898	16,858	17,113	16,943	C 02.00 (r060, c010) - [C 07.00 (r090, c220, s001) + C 07.00 (r110, c220, s001) + C 07.00 (r130, c220, s001)]
Of which the foundation IRB (FIRB) approach	0	0	0	0	C 02.00 (R250, c010) - [C 08.01 (r040, c260, s002) + C 08.01 (r050, c260, s002) + C 08.01 (r060, c260, s002)]
Of which the advanced IRB (AIRB) approach	0	0	0	0	C 02.00 (R310, c010) - [C 08.01 (r040, c260, s001) + C 08.01 (r050, c260, s001) + C 08.01 (r060, c260, s001)]
Of which equity IRB	0	0	0	0	C 02.00 (R420, c010)
Counterparty credit risk (CCR, excluding CVA) ²	22	24	23	41	C 07.00 (r090, c220, s001) + C 07.00 (r110, c220, s001) + C 07.00 (r130, c220, s001) + C 08.01 (r040, c260, s001) + C 08.01 (r050, c260, s001) + C 08.01 (r060, c260, s001) + C 08.01 (r040, c260, s002) + C 08.01 (r050, c260, s002) + C 08.01 (r060, c260, s002) + C 02.00 (R460, c010)]
Credit valuation adjustment - CVA	13	12	13	27	C 02.00 (R640, c010)
Settlement risk	0	0	0	0	C 02.00 (R490, c010)
Securitisation exposures in the banking book (after the cap)	0	0	0	0	C 02.00 (R470, c010)
Position, foreign exchange and commodities risks (Market risk)	0	0	0	0	C 02.00 (R520, c010)
Of which the standardised approach	0	0	0	0	C 02.00 (R530, c010)
Of which IMA	0	0	0	0	C 02.00 (R580, c010)
Of which securitisations and resecuritisations in the trading book	0	0	0	0	C 19.00_010_601*12.5+C 20.00_010_450*12.5+MAX(C 24.00_010_090,C 24.00_010_100,C 24.00_010_110)*12.5
Large exposures in the trading book	0	0	0	0	C 02.00 (R680, c010)
Operational risk	1,376	1,354	1,354	1,354	C 02.00 (R590, c010)
Of which basic indicator approach	0	0	0	0	C 02.00 (R600, c010)
Of which standardised approach	1,376	1,354	1,354	1,354	C 02.00 (R610, c010)
Of which advanced measurement approach	0	0	0	0	C 02.00 (R620, c010)
Other risk exposure amounts	0	0	0	0	C 02.00 (R630, c010) + C 02.00 (R690, c010)
Total	18,309	18,248	18,503	18,364	

¹ The positions "of which" are for information and do not need to sum up to Credit risk (excluding CCR and Securitisations)

² On-balance sheet exposures related to Free Deliveries [according to Article 379(1)] have not been included in "Counterparty Credit Risk (CCR, excluding CVA)". They are instead reported in the "Credit Risk (excluding CCR and Securitisations)" section.

2021 EU-wide Transparency Exercise

P&L

Ibercaja Banco, S.A.

(m€ EUR)	As of 30/09/2020	As of 31/12/2020	As of 31/03/2021	As of 30/06/2021
Interest income	372	495	113	225
Of which debt securities income	46	56	11	32
Of which loans and advances income	310	410	92	180
Interest expenses	54	73	17	31
(Of which deposits expenses)	65	85	20	34
(Of which debt securities issued expenses)	25	30	5	9
(Expenses on share capital repayable on demand)	0	0	0	0
Dividend income	3	5	2	7
Net Fee and commission income	288	395	103	213
Gains or (-) losses on derecognition of financial assets and liabilities not measured at fair value through profit or loss, and of non financial assets, net	14	126	32	32
Gains or (-) losses on financial assets and liabilities held for trading, net	1	1	0	0
Gains or (-) losses on financial assets and liabilities at fair value through profit or loss, net	-10	-10	0	0
Gains or (-) losses from hedge accounting, net	0	0	0	0
Exchange differences (gain or (-) loss), net	1	1	0	0
Net other operating income / (expenses)	65	32	8	-5
TOTAL OPERATING INCOME, NET	678	971	242	442
(Administrative expenses)	373	653	132	260
(Cash contributions to resolution funds and deposit guarantee schemes)	16	64	2	0
(Depreciation)	52	65	16	34
Modification gains or (-) losses, net	-2	-2	0	0
(Provisions or (-) reversal of provisions)	-27	-14	-3	4
(Payment commitments to resolution funds and deposit guarantee schemes)	0	0	0	0
(Commitments and guarantees given)	-2	-3	-3	-3
(Other provisions)	-25	-11	0	7
Of which pending legal issues and tax litigation ¹	0	0	0	0
Of which restructuring ²	0	0	0	0
(Increases or (-) decreases of the fund for general banking risks, net) ²	0	0	0	0
(Impairment or (-) reversal of impairment on financial assets not measured at fair value through profit or loss)	177	216	30	38
(Financial assets at fair value through other comprehensive income)	0	0	0	0
(Financial assets at amortised cost)	177	216	30	38
(Impairment or (-) reversal of impairment of investments in subsidiaries, joint ventures and associates and on non-financial assets)	2	1	1	3
(of which Goodwill)	0	0	0	0
Negative goodwill recognised in profit or loss	0	0	0	0
Share of the profit or (-) loss of investments in subsidiaries, joint ventures and associates	67	89	22	43
Profit or (-) loss from non-current assets and disposal groups classified as held for sale not qualifying as discontinued operations	-6	-20	-6	-10
PROFIT OR (-) LOSS BEFORE TAX FROM CONTINUING OPERATIONS	145	53	80	135
PROFIT OR (-) LOSS AFTER TAX FROM CONTINUING OPERATIONS	99	24	55	94
Profit or (-) loss after tax from discontinued operations	0	0	0	0
PROFIT OR (-) LOSS FOR THE YEAR	99	24	55	94
Of which attributable to owners of the parent	99	24	55	94

¹ Information available only as of end of the year

² For IFRS compliance banks "zero" in cell "Increases or (-) decreases of the fund for general banking risks, net" must be read as "n.a."

2021 EU-wide Transparency Exercise

Total Assets: fair value and impairment distribution

Ibercaja Banco, S.A.

(m€ EUR)		As of 30/09/2020				As of 31/12/2020				As of 31/03/2021				As of 30/06/2021				References
ASSETS:	Carrying amount	Fair value hierarchy			Carrying amount	Fair value hierarchy			Carrying amount	Fair value hierarchy			Carrying amount	Fair value hierarchy				
		Level 1	Level 2	Level 3		Level 1	Level 2	Level 3		Level 1	Level 2	Level 3		Level 1	Level 2	Level 3		
Cash, cash balances at central banks and other demand deposits	4,958				7,571				4,966				5,726				IAS 1.54 (i)	
Financial assets held for trading	6	0	6	0	6	0	6	0	4	0	4	0	4	0	4	0	IFRS 7.8(a)(i); IFRS 9 Appendix A	
Non-trading financial assets mandatorily at fair value through profit or loss	2	0	0	2	2	0	0	2	2	0	0	2	2	0	0	2	IFRS 7.8(a)(ii); IFRS 9.4.1.4	
Financial assets designated at fair value through profit or loss	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	IFRS 7.8(a)(i); IFRS 9.4.1.5	
Financial assets at fair value through other comprehensive income	498	305	162	30	488	297	162	29	935	746	160	29	852	683	140	29	IFRS 7.8(h); IFRS 9.4.1.2A	
Financial assets at amortised cost	41,156				39,540				41,193				40,931				IFRS 7.8(f); IFRS 9.4.1.2	
Derivatives – Hedge accounting	153	0	153	0	142	0	142	0	120	0	120	0	87	0	87	0	IFRS 9.6.2.1; Annex V.Part 1.2.2; Annex V.Part 1.26	
Fair value changes of the hedged items in portfolio hedge of interest rate risk	0				0				0				0				IAS 39.89A(a); IFRS 9.6.5.8	
Other assets ¹	3,488				3,481				3,451				3,442					
TOTAL ASSETS	50,261				51,229				50,671				51,043				IAS 1.9(a), IG 6	

⁽¹⁾ Portfolios, which are not GAAP specific, i.e., which are not applicable for IFRS reporting banks, are considered in the position "Other assets".

(m€ EUR)		As of 30/09/2020						As of 31/12/2020						As of 31/03/2021						As of 30/06/2021						References
		Gross carrying amount			Accumulated impairment			Gross carrying amount			Accumulated impairment			Gross carrying amount			Accumulated impairment			Gross carrying amount ⁽²⁾			Accumulated impairment ⁽²⁾			
Breakdown of financial assets by instrument and by counterparty sector ¹		Stage 1 Assets without significant increase in credit risk since initial recognition	Stage 2 Assets with significant increase in credit risk since initial recognition but not credit-impaired	Stage 3 Credit-impaired assets	Stage 1 Assets without significant increase in credit risk since initial recognition	Stage 2 Assets with significant increase in credit risk since initial recognition but not credit-impaired	Stage 3 Credit-impaired assets	Stage 1 Assets without significant increase in credit risk since initial recognition	Stage 2 Assets with significant increase in credit risk since initial recognition but not credit-impaired	Stage 3 Credit-impaired assets	Stage 1 Assets without significant increase in credit risk since initial recognition	Stage 2 Assets with significant increase in credit risk since initial recognition but not credit-impaired	Stage 3 Credit-impaired assets	Stage 1 Assets without significant increase in credit risk since initial recognition	Stage 2 Assets with significant increase in credit risk since initial recognition but not credit-impaired	Stage 3 Credit-impaired assets	Stage 1 Assets without significant increase in credit risk since initial recognition	Stage 2 Assets with significant increase in credit risk since initial recognition but not credit-impaired	Stage 3 Credit-impaired assets	Stage 1 Assets without significant increase in credit risk since initial recognition	Stage 2 Assets with significant increase in credit risk since initial recognition but not credit-impaired	Stage 3 Credit-impaired assets	Stage 1 Assets without significant increase in credit risk since initial recognition	Stage 2 Assets with significant increase in credit risk since initial recognition but not credit-impaired	Stage 3 Credit-impaired assets	
Financial assets at fair value through other comprehensive income	Debt securities	173	0	0	0	0	0	165	0	0	0	0	0	579	0	0	0	0	0	512	0	0	0	0	0	Annex V.Part 1.31, 44(b)
	Loans and advances	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Annex V.Part 1.32, 44(a)
Financial assets at amortised cost	Debt securities	9,568	0	0	0	0	0	8,314	0	0	0	0	0	9,620	0	0	0	0	0	9,590	0	0	0	0	0	Annex V.Part 1.31, 44(b)
	Loans and advances	29,857	1,251	1,156	-101	-68	-507	29,179	1,681	1,011	-52	-132	-461	29,559	1,700	955	-53	-131	-456	29,446	1,605	894	-53	-127	-424	Annex V.Part 1.32, 44(a)

⁽¹⁾ This table covers IFRS 9 specific information and as such only applies for IFRS reporting banks.⁽²⁾ From June 2021, the gross carrying amount of assets and accumulated impairments that are purchased or originated as credit-impaired at initial recognition are not included in the impairment stages, as it was the case in previous periods.

2021 EU-wide Transparency Exercise

Breakdown of liabilities

Ibercaja Banco, S.A.

(mln EUR)

LIABILITIES:	Carrying amount				References
	As of 30/09/2020	As of 31/12/2020	As of 31/03/2021	As of 30/06/2021	
Financial liabilities held for trading	7	6	10	4	IFRS 7.8 (e) (ii); IFRS 9.BA.6
Trading financial liabilities ¹	0	0	0	0	Accounting Directive art 8(1)(a),(3),(6)
Financial liabilities designated at fair value through profit or loss	0	0	0	0	IFRS 7.8 (e)(i); IFRS 9.4.2.2
Financial liabilities measured at amortised cost	46,205	46,997	46,563	46,937	IFRS 7.8(g); IFRS 9.4.2.1
Non-trading non-derivative financial liabilities measured at a cost-based method ¹	0	0	0	0	Accounting Directive art 8(3)
Derivatives – Hedge accounting	210	216	132	146	IFRS 9.6.2.1; Annex V.Part 1.26
Fair value changes of the hedged items in portfolio hedge of interest rate risk	40	38	32	28	IAS 39.89A(b), IFRS 9.6.5.8
Provisions	221	393	376	335	IAS 37.10; IAS 1.54(l)
Tax liabilities	156	149	148	148	IAS 1.54(n-o)
Share capital repayable on demand	0	0	0	0	IAS 32 IE 33; IFRIC 2; Annex V.Part 2.12
Other liabilities	121	212	159	158	Annex V.Part 2.13
Liabilities included in disposal groups classified as held for sale	0	0	0	0	IAS 1.54 (p); IFRS 5.38, Annex V.Part 2.14
Haircuts for trading liabilities at fair value ¹	0	0	0	0	Annex V Part 1.29
TOTAL LIABILITIES	46,960	48,011	47,419	47,756	IAS 1.9(b); IG 6
TOTAL EQUITY	3,302	3,218	3,252	3,287	IAS 1.9(c), IG 6
TOTAL EQUITY AND TOTAL LIABILITIES	50,261	51,229	50,671	51,043	IAS 1.IG6

(1) Portfolios which are nGAAP specific, i.e. which are not applicable for IFRS reporting banks

2021 EU-wide Transparency Exercise

Breakdown of liabilities

Ibercaja Banco, S.A.

(mln EUR)

Breakdown of financial liabilities by instrument and by counterparty sector		Carrying amount				References
		As of 30/09/2020	As of 31/12/2020	As of 31/03/2021	As of 30/06/2021	
Derivatives		217	222	142	150	IFRS 9.BA.7(a); CRR Annex II
Short positions	Equity instruments	0	0	0	0	IAS 32.11; ECB/2013/33 Annex 2.Part 2.4-5
	Debt securities	0	0	0	0	Annex V.Part 1.31
Deposits	Central banks	5,385	5,371	5,917	5,902	Annex V.Part 1.42(a), 44(c)
	of which: Current accounts / overnight deposits	0	0	0	0	ECB/2013/33 Annex 2.Part 2.9.1
	General governments	1,577	1,431	1,326	1,159	Annex V.Part 1.42(b), 44(c)
	of which: Current accounts / overnight deposits	1,483	1,345	1,245	1,081	ECB/2013/33 Annex 2.Part 2.9.1
	Credit institutions	1,085	1,208	471	1,409	Annex V.Part 1.42(c),44(c)
	of which: Current accounts / overnight deposits	30	49	164	180	ECB/2013/33 Annex 2.Part 2.9.1
	Other financial corporations	2,685	2,697	2,065	1,612	Annex V.Part 1.42(d),44(c)
	of which: Current accounts / overnight deposits	812	834	494	420	ECB/2013/33 Annex 2.Part 2.9.1
	Non-financial corporations	3,987	4,199	4,219	3,926	Annex V.Part 1.42(e), 44(c)
	of which: Current accounts / overnight deposits	3,845	4,069	4,101	3,827	ECB/2013/33 Annex 2.Part 2.9.1
	Households	29,013	29,887	30,017	30,038	Annex V.Part 1.42(f), 44(c)
	of which: Current accounts / overnight deposits	25,918	26,942	27,239	27,471	Annex V.Part 1.42(f), 44(c)
Debt securities issued		1,380	1,369	1,341	1,329	Annex V.Part 1.37, Part 2.98
Of which: Subordinated Debt securities issued		506	509	512	513	Annex V.Part 1.37
Other financial liabilities		1,094	835	1,208	1,563	Annex V.Part 1.38-41
TOTAL FINANCIAL LIABILITIES		46,422	47,219	46,705	47,087	

2021 EU-wide Transparency Exercise

Market Risk
Ibercaja Banco, S.A.

(mln EUR)	SA		IM										IM									
	TOTAL RISK EXPOSURE AMOUNT	TOTAL RISK EXPOSURE AMOUNT	VaR (Memorandum item)		STRESSED VaR (Memorandum item)		INCREMENTAL DEFAULT AND MIGRATION RISK CAPITAL CHARGE		ALL PRICE RISKS CAPITAL CHARGE FOR CTP			TOTAL RISK EXPOSURE AMOUNT	VaR (Memorandum item)		STRESSED VaR (Memorandum item)		INCREMENTAL DEFAULT AND MIGRATION RISK CAPITAL CHARGE		ALL PRICE RISKS CAPITAL CHARGE FOR CTP			TOTAL RISK EXPOSURE AMOUNT
			MULTIPLICATION FACTOR (mc) x AVERAGE OF PREVIOUS 60 WORKING DAYS (VaRavg)	PREVIOUS DAY (VaRt-1)	MULTIPLICATION FACTOR (ms) x AVERAGE OF PREVIOUS 60 WORKING DAYS (SVaRavg)	LATEST AVAILABLE (SVaRt-1)	12 WEEKS AVERAGE MEASURE	LAST MEASURE	FLOOR	12 WEEKS AVERAGE MEASURE	LAST MEASURE		MULTIPLICATION FACTOR (mc) x AVERAGE OF PREVIOUS 60 WORKING DAYS (VaRavg)	PREVIOUS DAY (VaRt-1)	MULTIPLICATION FACTOR (ms) x AVERAGE OF PREVIOUS 60 WORKING DAYS (SVaRavg)	LATEST AVAILABLE (SVaRt-1)	12 WEEKS AVERAGE MEASURE	LAST MEASURE	FLOOR	12 WEEKS AVERAGE MEASURE	LAST MEASURE	
As of 30/09/2020	As of 31/12/2020	As of 30/09/2020										As of 31/12/2020										
Traded debt Instruments	0	0	0	0	0	0	0						0	0	0	0						
Of which: General risk	0	0	0	0	0	0	0						0	0	0	0						
Of which: Specific risk	0	0	0	0	0	0	0						0	0	0	0						
Equities	0	0	0	0	0	0	0						0	0	0	0						
Of which: General risk	0	0	0	0	0	0	0						0	0	0	0						
Of which: Specific risk	0	0	0	0	0	0	0						0	0	0	0						
Foreign exchange risk	0	0	0	0	0	0	0						0	0	0	0						
Commodities risk	0	0	0	0	0	0	0						0	0	0	0						
Total	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
As of 31/03/2021	As of 30/06/2021	As of 31/03/2021										As of 30/06/2021										
Traded Debt Instruments	0	0	0	0	0	0	0						0	0	0	0						
Of which: General risk	0	0	0	0	0	0	0						0	0	0	0						
Of which: Specific risk	0	0	0	0	0	0	0						0	0	0	0						
Equities	0	0	0	0	0	0	0						0	0	0	0						
Of which: General risk	0	0	0	0	0	0	0						0	0	0	0						
Of which: Specific risk	0	0	0	0	0	0	0						0	0	0	0						
Foreign exchange risk	0	0	0	0	0	0	0						0	0	0	0						
Commodities risk	0	0	0	0	0	0	0						0	0	0	0						
Total	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Market risk template does not include CLU positions under the particular approach for position risk in CLUs (Articles 348(1), 350 (3) c) and 364 (2) a) CRR), which instead are included in the RWA OV1 template.

2021 EU-wide Transparency Exercise

Credit Risk - Standardised Approach

Ibercaja Banco, S.A.

		Standardised Approach							
		As of 30/09/2020				As of 31/12/2020			
		Original Exposure ⁽¹⁾	Exposure Value ⁽¹⁾	Risk exposure amount	Value adjustments and provisions	Original Exposure ⁽¹⁾	Exposure Value ⁽¹⁾	Risk exposure amount	Value adjustments and provisions
(mln EUR, %)									
Consolidated data	Central governments or central banks	13,078	15,740	998		14,380	17,188	1,072	
	Regional governments or local authorities	1,202	968	0		993	758	0	
	Public sector entities	653	637	4		700	687	29	
	Multilateral Development Banks	1	12	0		1	11	0	
	International Organisations	0	0	0		0	0	0	
	Institutions	294	400	86		365	475	95	
	Corporates	6,683	3,452	2,867		6,810	3,511	2,955	
	of which: SME	2,720	1,927	1,550		2,677	1,884	1,534	
	Retail	7,295	4,618	3,024		7,232	4,459	2,916	
	of which: SME	4,225	2,439	1,389		4,288	2,401	1,372	
	Secured by mortgages on immovable property	19,021	18,952	6,628		18,976	18,896	6,610	
	of which: SME	1,103	1,088	364		1,092	1,076	362	
	Exposures in default	1,123	608	622	486	988	516	526	446
	Items associated with particularly high risk	344	263	394		326	247	370	
	Covered bonds	26	26	5		22	22	11	
	Claims on institutions and corporates with a ST credit assessment	1	1	0		0	0	0	
	Collective investments undertakings (CIU)	25	25	25		20	20	20	
	Equity	793	793	797		765	765	769	
	Other exposures	2,175	1,897	1,468		2,156	1,883	1,508	
Standardised Total ⁽²⁾		52,715	48,392	16,919	978	53,734	49,436	16,880	940

⁽¹⁾ Original exposure, unlike Exposure value, is reported before taking into account any effect due to credit conversion factors or credit risk mitigation techniques (e.g. substitution effects).

⁽²⁾ Standardised Total does not include the Securitisation position unlike in the results prior to the 2019 exercise.

2021 EU-wide Transparency Exercise

Credit Risk - Standardised Approach

Ibercaja Banco, S.A.

		Standardised Approach							
		As of 31/03/2021				As of 30/06/2021			
		Original Exposure ¹	Exposure Value ¹	Risk exposure amount	Value adjustments and provisions	Original Exposure ¹	Exposure Value ¹	Risk exposure amount	Value adjustments and provisions
(mln EUR, %)									
Consolidated data	Central governments or central banks	13,342	16,294	1,082		14,108	17,046	1,078	
	Regional governments or local authorities	1,147	964	0		1,169	868	0	
	Public sector entities	704	687	29		705	686	29	
	Multilateral Development Banks	1	10	0		1	9	0	
	International Organisations	0	0	0		0	0	0	
	Institutions	325	436	87		409	521	102	
	Corporates	7,304	4,060	3,408		7,435	4,061	3,404	
	of which: SME	2,841	1,989	1,621		2,916	2,026	1,655	
	Retail	7,082	4,278	2,794		6,937	4,131	2,698	
	of which: SME	4,228	2,315	1,322		4,160	2,231	1,273	
	Secured by mortgages on immovable property	18,635	18,561	6,494		18,544	18,473	6,466	
	of which: SME	1,035	1,020	342		1,022	1,011	342	
	Exposures in default	1,056	575	601	445	996	541	562	417
	Items associated with particularly high risk	302	236	355		290	225	338	
	Covered bonds	21	21	4		21	21	4	
	Claims on institutions and corporates with a ST credit assessment	0	0	0		0	0	0	
Collective investments undertakings (CIU)		54	54	54		778	190	56	
Equity		765	765	769		771	771	775	
Other exposures		2,246	1,973	1,460		2,207	1,957	1,471	
Standardised Total ²		52,983	48,914	17,136	931	54,373	49,501	16,982	875

⁽¹⁾ Original exposure, unlike Exposure value, is reported before taking into account any effect due to credit conversion factors or credit risk mitigation techniques (e.g. substitution effects).

⁽²⁾ Standardised Total does not include the Securitisation position unlike in the results prior to the 2019 exercise.

2021 EU-wide Transparency Exercise

Credit Risk - IRB Approach

Ibercaja Banco, S.A.

		IRB Approach											
		As of 30/09/2020						As of 31/12/2020					
		Original Exposure ¹		Exposure Value ¹	Risk exposure amount		Value adjustments and provisions	Original Exposure ¹		Exposure Value ¹	Risk exposure amount		Value adjustments and provisions
		Of which: defaulted			Of which: defaulted			Of which: defaulted			Of which: defaulted		
Consolidated data	(mln EUR, %)												
	Central banks and central governments	0	0	0	0	0	0	0	0	0	0	0	0
	Institutions	0	0	0	0	0	0	0	0	0	0	0	0
	Corporates	0	0	0	0	0	0	0	0	0	0	0	0
	Corporates - Of Which: Specialised Lending	0	0	0	0	0	0	0	0	0	0	0	0
	Corporates - Of Which: SME	0	0	0	0	0	0	0	0	0	0	0	0
	Retail	0	0	0	0	0	0	0	0	0	0	0	0
	Retail - Secured on real estate property	0	0	0	0	0	0	0	0	0	0	0	0
	Retail - Secured on real estate property - Of Which: SME	0	0	0	0	0	0	0	0	0	0	0	0
	Retail - Secured on real estate property - Of Which: non-SME	0	0	0	0	0	0	0	0	0	0	0	0
	Retail - Qualifying Revolving	0	0	0	0	0	0	0	0	0	0	0	0
	Retail - Other Retail	0	0	0	0	0	0	0	0	0	0	0	0
	Retail - Other Retail - Of Which: SME	0	0	0	0	0	0	0	0	0	0	0	0
	Retail - Other Retail - Of Which: non-SME	0	0	0	0	0	0	0	0	0	0	0	0
	Equity	0	0	0	0	0	0	0	0	0	0	0	0
	Other non credit-obligation assets												
IRB Total ²				0						0			

⁽¹⁾ Original exposure, unlike Exposure value, is reported before taking into account any effect due to credit conversion factors or credit risk mitigation techniques (e.g. substitution effects).

⁽²⁾ IRB Total does not include the Securitisation position unlike in the results prior to the 2019 exercise.

2021 EU-wide Transparency Exercise

Credit Risk - IRB Approach

Ibercaja Banco, S.A.

		IRB Approach									
		As of 31/03/2021					As of 30/06/2021				
	(mln EUR, %)	Original Exposure ¹	Exposure Value ¹	Risk exposure amount	Value adjustments and provisions		Original Exposure ¹	Exposure Value ¹	Risk exposure amount	Value adjustments and provisions	
		Of which: defaulted		Of which: defaulted			Of which: defaulted		Of which: defaulted		
Consolidated data	Central banks and central governments	0	0	0	0	0	0	0	0	0	0
	Institutions	0	0	0	0	0	0	0	0	0	0
	Corporates	0	0	0	0	0	0	0	0	0	0
	Corporates - Of Which: Specialised Lending	0	0	0	0	0	0	0	0	0	0
	Corporates - Of Which: SME	0	0	0	0	0	0	0	0	0	0
	Retail	0	0	0	0	0	0	0	0	0	0
	Retail - Secured on real estate property	0	0	0	0	0	0	0	0	0	0
	Retail - Secured on real estate property - Of Which: SME	0	0	0	0	0	0	0	0	0	0
	Retail - Secured on real estate property - Of Which: non-SME	0	0	0	0	0	0	0	0	0	0
	Retail - Qualifying Revolving	0	0	0	0	0	0	0	0	0	0
	Retail - Other Retail	0	0	0	0	0	0	0	0	0	0
	Retail - Other Retail - Of Which: SME	0	0	0	0	0	0	0	0	0	0
	Retail - Other Retail - Of Which: non-SME	0	0	0	0	0	0	0	0	0	0
	Equity	0	0	0	0	0	0	0	0	0	0
	Other non credit-obligation assets			0					0		
	IRB Total ²			0					0		

⁽¹⁾ Original exposure, unlike Exposure value, is reported before taking into account any effect due to credit conversion factors or credit risk mitigation techniques (e.g. substitution effects).

⁽²⁾ IRB Total does not include the Securitisation position unlike in the results prior to the 2019 exercise.

As of 31/12/2020

[illegible]

Ibercaja Banco, S.A.

(min EUR)

Ibercaja Banco, S.A.

As of 31/12/2020

[illegible]

2021 EU-wide Transparency Exercise
General governments exposures by country of the counterparty

Ibercaja Banco, S.A.

As of 31/12/2020

(mln EUR)		As of 31/12/2020												
		Direct exposures												Risk weighted exposure amount
		On balance sheet						Derivatives				Off balance sheet		
		Total gross carrying amount of non-derivative financial assets	Total carrying amount of non-derivative financial assets (net of short positions)	of which: Financial assets held for trading	of which: Financial assets designated at fair value through profit or loss	of which: Financial assets at fair value through other comprehensive income	of which: Financial assets at amortised cost	Derivatives with positive fair value		Derivatives with negative fair value		Off-balance sheet exposures		
Carrying amount	Notional amount							Carrying amount	Notional amount	Nominal	Provisions			
Residual Maturity	Country / Region													
[0 - 3M]	Africa													
[3M - 1Y]														
[1Y - 2Y]														
[2Y - 3Y]														
[3Y - 5Y]														
[5Y - 10Y]														
[10Y - more														
Total														
[0 - 3M]	Others	0	0	0	0	0	0	0	0	0	0	0	0	0
[3M - 1Y]		120	120	0	0	0	120	0	0	0	0	0	0	0
[1Y - 2Y]		220	220	0	0	2	217	0	0	0	0	0	0	0
[2Y - 3Y]		4	4	0	0	0	4	0	0	0	0	0	0	0
[3Y - 5Y]		12	12	0	0	4	7	0	0	0	0	0	0	0
[5Y - 10Y]		259	259	0	0	0	259	0	0	0	0	0	0	0
[10Y - more		78	78	0	0	0	78	0	0	0	0	0	0	0
Total			693	693	0	0	6	687	0	0	0	0	0	0

Notes and definitions

Information disclosed in this template is sourced from COREP template C 33, introduced with the reporting framework 2.7, applicable for reports as of 31 march 2018.

(1) Information on sovereign exposures is only available for institutions that have sovereign exposures of at least 1% of total "Debt securities and loans receivables". Country of breakdown is only available for institutions that hold non-domestic sovereign exposures of 10% or more compared to total sovereign exposures. Where the latter threshold is not met, information is disclosed through the aggregate "Others".

(2) The exposures reported cover only exposures to central, regional and local governments on immediate borrower basis, and do not include exposures to other counterpart with full or partial government guarantees

(3) The banks disclose the exposures in the "Financial assets held for trading" portfolio after offsetting the cash short positions having the same maturities.

(4) The exposures reported include the positions towards counterpart (other than sovereign) on sovereign credit risk (i.e. CDS, financial guarantees) booked in all the accounting portfolio (on-off balance sheet). In respect of the denomination and or accounting classification of the positions the economic substance over the form must be used as a criteria for the identification of the exposures to be included in this column. This item does not include exposures to counterpart (other than sovereign) with full or partial government guarantees by central, regional and local governments

(5) Residual countries not reported separately in the Transparency exercise

Regions:

Other advanced non EEA: Israel, Korea, New Zealand, Russia, San Marino, Singapore and Taiwan.

Other CEE non EEA: Albania, Bosnia and Herzegovina, FYR Macedonia, Montenegro, Serbia and Turkey.

Middle East: Bahrain, Djibouti, Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, Oman, Qatar, Saudi Arabia, Sudan, Syria, United Arab Emirates and Yemen.

Latin America: Argentina, Belize, Bolivia, Brazil, Chile, Colombia, Costa Rica, Dominica, Dominican Republic, Ecuador, El Salvador, Grenada, Guatemala, Guyana, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, St. Kitts and Nevis, St. Lucia, St. Vincent and the Grenadines, Suriname, Trinidad and Tobago, Uruguay, Venezuela, Antigua And Barbuda, Aruba, Bahamas, Barbados, Cayman Islands, Cuba, French Guiana, Guadeloupe, Martinique, Puerto Rico, Saint Barthélemy, Turks And Caicos Islands, Virgin Islands (British), Virgin Islands (U.S.).

Africa: Algeria, Egypt, Morocco, South Africa, Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo, The Democratic Republic Of The, Côte D'Ivoire, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritius, Mauritania, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome And Principe, Senegal, Seychelles, Sierra Leone, South Sudan, Swaziland, Tanzania, United Republic Of, Togo, Uganda, Zambia, Zimbabwe and Tunisia.

(6) The columns 'Total carrying amount of non-derivative financial assets (net of short positions)' provide information on a net basis, whilst the related 'of which' positions present information on a gross basis.

(7) The values for the 'Other' bucket is calculated subtracting from the reported Total the breakdown of the listed countries. As a result of precision and rounding in the calculation we accept an approximation in the order of e04.

As of 30/06/2021

[illegible]

As of 30/06/2021

[illegible]

[illegible]

As of 30/06/2021

[illegible]

2021 EU-wide Transparency Exercise
General governments exposures by country of the counterparty

Ibercaja Banco, S.A.

As of 30/06/2021

(mln EUR)		As of 30/06/2021												
		Direct exposures											Risk weighted exposure amount	
		On balance sheet						Derivatives				Off balance sheet		
		Total gross carrying amount of non-derivative financial assets	Total carrying amount of non-derivative financial assets (net of short positions)	of which: Financial assets held for trading	of which: Financial assets designated at fair value through profit or loss	of which: Financial assets at fair value through other comprehensive income	of which: Financial assets at amortised cost	Derivatives with positive fair value		Derivatives with negative fair value		Off-balance sheet exposures		
Carrying amount	Notional amount							Carrying amount	Notional amount	Nominal	Provisions			
Residual Maturity	Country / Region													
[0 - 3M] [3M - 1Y] [1Y - 2Y] [2Y - 3Y] [3Y - 5Y] [5Y - 10Y] [10Y - more] Total	Africa													
[0 - 3M] [3M - 1Y] [1Y - 2Y] [2Y - 3Y] [3Y - 5Y] [5Y - 10Y] [10Y - more] Total	Others	0 113 4 0 0 0 0	0 113 4 0 0 0 0	0 0 0 0 0 0 0	0 0 0 0 0 0 0	0 0 0 0 0 0 0	0 4 0 0 0 0 0	0 0 0 0 0 0 0	0 0 0 0 0 0 0	0 0 0 0 0 0 0	0 0 0 0 0 0 0	0 0 0 0 0 0 0	0 0 0 0 0 0 0	
		117	117	0	0	0	4	0	0	0	0	0	0	2

Notes and definitions

Information disclosed in this template is sourced from COREP template C 33, introduced with the reporting framework 2.7, applicable for reports as of 31 march 2018.

(1) Information on sovereign exposures is only available for institutions that have sovereign exposures of at least 1% of total "Debt securities and loans receivables". Country of breakdown is only available for institutions that hold non-domestic sovereign exposures of 10% or more compared to total sovereign exposures. Where the latter threshold is not met, information is disclosed through the aggregate "Others".

(2) The exposures reported cover only exposures to central, regional and local governments on immediate borrower basis, and do not include exposures to other counterpart with full or partial government guarantees

(3) The banks disclose the exposures in the "Financial assets held for trading" portfolio after offsetting the cash short positions having the same maturities.

(4) The exposures reported include the positions towards counterpart (other than sovereign) on sovereign credit risk (i.e. CDS, financial guarantees) booked in all the accounting portfolio (on-off balance sheet). Irrespective of the denomination and or accounting classification of the positions the economic substance over the form must be used as a criteria for the identification of the exposures to be included in this column. This item does not include exposures to counterparts (other than sovereign) with full or partial government guarantees by central, regional and local governments

(5) Residual countries not reported separately in the Transparency exercise

Regions:

Other advanced non EEA: Israel, Korea, New Zealand, Russia, San Marino, Singapore and Taiwan.

Other CEE non EEA: Albania, Bosnia and Herzegovina, FYR Macedonia, Montenegro, Serbia and Turkey.

Middle East: Bahrain, Djibouti, Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, Oman, Qatar, Saudi Arabia, Sudan, Syria, United Arab Emirates and Yemen.

Latin America: Argentina, Belize, Bolivia, Brazil, Chile, Colombia, Costa Rica, Dominica, Dominican Republic, Ecuador, El Salvador, Grenada, Guatemala, Guyana, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, St. Kitts and Nevis, St. Lucia, St. Vincent and the Grenadines, Suriname, Trinidad and Tobago, Uruguay, Venezuela, Antigua And Barbuda, Aruba, Bahamas, Barbados, Cayman Islands, Cuba, French Guiana, Guadeloupe, Martinique, Puerto Rico, Saint Barthélemy, Turks And Caicos Islands, Virgin Islands (British), Virgin Islands (U.S.).

Africa: Algeria, Egypt, Morocco, South Africa, Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo, The Democratic Republic Of The, Côte D'Ivoire, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritius, Mauritania, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome And Principe, Senegal, Seychelles, Sierra Leone, South Sudan, Swaziland, Tanzania, United Republic Of, Togo, Uganda, Zambia, Zimbabwe and Tunisia.

(6) The columns 'Total carrying amount of non-derivative financial assets (net of short positions)' provide information on a net basis, whilst the related 'of which' positions present information on a gross basis.

(7) The values for the 'Other' bucket is calculated subtracting from the reported Total the breakdown of the listed countries. As a result of precision and rounding in the calculation we accept an approximation in the order of e04.

2021 EU-wide Transparency Exercise

Performing and non-performing exposures

Ibercaja Banco, S.A.

(mln EUR)	As of 30/09/2020									As of 31/12/2020								
	Gross carrying amount					Accumulated impairment, accumulated changes in fair value due to credit risk and provisions ¹			Collaterals and financial guarantees received on non-performing exposures	Gross carrying amount					Accumulated impairment, accumulated changes in fair value due to credit risk and provisions ¹			Collaterals and financial guarantees received on non-performing exposures
	Of which performing but past due >30 days and <=90 days	Of which non-performing ¹			On performing exposures ²	On non-performing exposures ³	Of which Stage 3	Of which performing but past due >30 days and <=90 days		Of which non-performing ¹			On performing exposures ²	On non-performing exposures ³	Of which Stage 3			
		Of which: defaulted	Of which Stage 3							Of which: defaulted	Of which Stage 3							
Cash balances at central banks and other demand deposits	4,759	0	0	0	0	0	0	0	0	7,332	0	0	0	0	0	0	0	0
Debt securities (including at amortised cost and fair value)	9,741	0	0	0	0	0	0	0	0	8,479	0	0	0	0	0	0	0	0
Central banks	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
General governments	7,931	0	0	0	0	0	0	0	0	6,675	0	0	0	0	0	0	0	0
Credit institutions	71	0	0	0	0	0	0	0	0	62	0	0	0	0	0	0	0	0
Other financial corporations	1,675	0	0	0	0	0	0	0	0	1,675	0	0	0	0	0	0	0	0
Non-financial corporations	64	0	0	0	0	0	0	0	0	67	0	0	0	0	0	0	0	0
Loans and advances(including at amortised cost and fair value)	32,269	138	1,158	1,158	1,156	170	509	507	530	31,875	161	1,013	1,013	1,011	184	463	461	491
Central banks	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
General governments	841	0	1	1	1	0	1	1	0	735	0	1	1	1	0	1	1	0
Credit institutions	220	0	0	0	0	0	0	0	0	283	0	0	0	0	0	0	0	0
Other financial corporations	1,883	0	0	0	0	0	0	0	0	1,824	0	0	0	0	0	0	0	0
Non-financial corporations	6,901	22	461	461	459	110	288	285	69	6,938	23	403	403	401	95	255	252	104
of which: small and medium-sized enterprises at amortised cost	5,509	21	435	435	435	94	270	270	68	5,388	21	377	377	377	80	235	235	103
of which: Loans collateralised by commercial immovable property at amortised cost	1,785	8	181	181	181	15	87	87	48	1,693	8	149	149	149	15	67	67	79
Households	22,424	116	696	696	696	59	220	220	461	22,095	138	609	609	609	90	207	207	387
of which: Loans collateralised by residential immovable property at amortised cost	19,397	101	591	591	591	38	153	153	438	19,177	123	510	510	510	67	140	140	358
of which: Credit for consumption at amortised cost	806	6	32	32	32	10	13	13	14	808	5	30	30	30	12	13	13	14
DEBT INSTRUMENTS other than HFT	46,768	138	1,158	1,158	1,156	170	509	507	530	47,686	161	1,013	1,013	1,011	185	463	461	491
OFF-BALANCE SHEET EXPOSURES	4,153		48	48	48	7	13	13	3	4,177		42	42	42	7	12	12	3

⁽¹⁾ For the definition of non-performing exposures please refer to COMMISSION IMPLEMENTING REGULATION (EU) 2015/227 of 9 January 2015, ANNEX V, Part 2-Template related instructions, subtable 29⁽²⁾ Institutions report here collective allowances for incurred but not reported losses (instruments at amortised cost) and changes in fair value of performing exposures due to credit risk and provisions (instruments at fair value other than HFT)⁽³⁾ Institutions report here specific allowances for financial assets, individually and collectively estimated (instruments at amortised cost) and changes in fair value of NPE due to credit risk and provisions (instruments at fair value other than HFT)⁽⁴⁾ For the on-balance sheet items, accumulated impairments and accumulated negative changes in fair value due to credit risk are disclosed with a positive sign if they are decreasing assets. Following this sign convention, information is disclosed with the opposite sign of what is reported according to the FINREP framework (templates F 18.00 / F 19.00), which follows a sign convention based on a credit/debit convention, as explained in Annex V, Part 1 paragraphs 9 and 10 of Regulation (EU) No 680/2014 - ITS on Supervisory reporting. However, for the off-balance sheet instruments, the same item ("Accumulated impairment, accumulated changes in fair value due to credit risk and provisions") is disclosed consistently with the FINREP sign convention. This is because, based on this sign convention, the provisions on off-balance sheet commitments are generally reported with a positive sign.⁽⁵⁾ From June 2021, the gross carrying amount of assets and accumulated impairments that are purchased or originated as credit-impaired at initial recognition are not included in the impairment stages, as it was the case in previous periods.

2021 EU-wide Transparency Exercise

Performing and non-performing exposures

Ibercaja Banco, S.A.

	As of 31/03/2021										As of 30/06/2021									
	Gross carrying amount					Accumulated impairment, accumulated changes in fair value due to credit risk and provisions ¹		Collaterals and financial guarantees received on non-performing exposures	Gross carrying amount ⁵					Accumulated impairment, accumulated changes in fair value due to credit risk and provisions ^{5,6}		Collaterals and financial guarantees received on non-performing exposures				
	Of which performing but past due >30 days and <=90 days	Of which non-performing ¹			On performing exposures ²	On non-performing exposures ³	Of which performing but past due >30 days and <=90 days		Of which non-performing ¹			On performing exposures ²	On non-performing exposures ³							
		Of which: defaulted	Of which Stage 3						Of which: defaulted	Of which Stage 3										
(mln EUR)																				
Cash balances at central banks and other demand deposits	4,741	0	0	0	0	0	0	0	0	5,542	0	0	0	0	0	0	0	0		
Debt securities (including at amortised cost and fair value)	10,198	0	0	0	0	0	0	0	0	10,102	0	0	0	0	0	0	0	0		
Central banks	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
General governments	10,063	0	0	0	0	0	0	0	0	9,970	0	0	0	0	0	0	0	0		
Credit institutions	58	0	0	0	0	0	0	0	0	60	0	0	0	0	0	0	0	0		
Other financial corporations	8	0	0	0	0	0	0	0	0	8	0	0	0	0	0	0	0	0		
Non-financial corporations	69	0	0	0	0	0	0	0	0	64	0	0	0	0	0	0	0	0		
Loans and advances (including at amortised cost and fair value)	32,217	158	1,072	1,072	955	178	463	456	554	31,948	68	1,011	1,010	894	173	432	424	528		
Central banks	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
General governments	867	0	1	1	1	0	1	1	0	788	0	1	1	1	0	1	1	0		
Credit institutions	349	0	0	0	0	0	0	0	0	379	0	0	0	0	0	0	0	0		
Other financial corporations	1,830	0	0	0	0	0	0	0	0	1,910	0	0	0	0	0	0	0	0		
Non-financial corporations	7,442	25	412	412	376	93	259	256	121	7,311	12	386	385	354	93	230	227	116		
of which: small and medium-sized enterprises at amortised cost	5,488	23	385	385	354	79	238	236	119	5,391	12	358	356	332	77	209	208	111		
of which: Loans collateralised by commercial immovable property at amortised cost	1,718	7	156	156	138	14	64	63	89	1,714	1	145	144	132	13	63	63	81		
Households	21,728	132	659	659	578	84	203	199	433	21,560	56	624	624	539	80	201	197	412		
of which: Loans collateralised by residential immovable property at amortised cost	18,869	120	548	548	482	62	136	133	399	18,708	51	519	519	450	59	136	133	380		
of which: Credit for consumption at amortised cost	778	4	34	34	29	11	13	12	16	781	2	33	33	28	11	13	12	16		
DEBT INSTRUMENTS other than HFT	47,156	158	1,072	1,072	955	178	463	456	554	47,591	68	1,011	1,010	894	174	432	424	528		
OFF-BALANCE SHEET EXPOSURES	3,977		49	48	38	7	10	10	13	4,266		45	45	37	7	10	10	10		

(1) For the definition of non-performing exposures please refer to COMMISSION IMPLEMENTING REGULATION (EU) 2015/227 of 9 January 2015, ANNEX V, Part 2-Template related instructions, subtitle 29

(2) Institutions report here collective allowances for incurred but not reported losses (instruments at amortised cost) and changes in fair value of performing exposures due to credit risk and provisions (instruments at fair value other than HFT)

(3) Institutions report here specific allowances for financial assets, individually and collectively estimated (instruments at amortised cost) and changes in fair value of NPE due to credit risk and provisions (instruments at fair value other than HFT)

(4) For the on-balance sheet items, accumulated impairments and accumulated negative changes in fair value due to credit risk are disclosed with a positive sign if they are decreasing assets. Following this sign convention, information is disclosed with the opposite sign of what is reported according to the FINREP framework (templates F 18.00 / F 19.00), which follows a sign convention based on a credit/debit convention, as explained in Annex V, Part 1 paragraphs 9 and 10 of Regulation (EU) No 680/2014 - ITS on Supervisory reporting. However, for the off-balance sheet instruments, the same item (Accumulated impairment, accumulated changes in fair value due to credit risk and provisions) is disclosed consistently with the FINREP sign convention. This is because, based on this sign convention, the provisions on off-balance sheet commitments are generally reported with a positive sign.

(5) From June 2021, the gross carrying amount of assets and accumulated impairments that are purchased or originated as credit-impaired at initial recognition are not included in the impairment stages, as it was the case in previous periods.

2021 EU-wide Transparency Exercise

Forborne exposures

Ibercaja Banco, S.A.

	As of 30/09/2020						As of 31/12/2020					
	Gross carrying amount of exposures with forbearance measures		Accumulated impairment, accumulated changes in fair value due to credit risk and provisions for exposures with forbearance measures ²		Collateral and financial guarantees received on exposures with forbearance measures		Gross carrying amount of exposures with forbearance measures		Accumulated impairment, accumulated changes in fair value due to credit risk and provisions for exposures with forbearance measures ²		Collateral and financial guarantees received on exposures with forbearance measures	
		Of which non-performing exposures with forbearance measures		Of which on non-performing exposures with forbearance measures		Of which collateral and financial guarantees received on non-performing exposures with forbearance measures		Of which non-performing exposures with forbearance measures		Of which on non-performing exposures with forbearance measures		Of which collateral and financial guarantees received on non-performing exposures with forbearance measures
(mln EUR)												
Cash balances at central banks and other demand deposits	0	0	0	0	0	0	0	0	0	0	0	0
Debt securities (including at amortised cost and fair value)	0	0	0	0	0	0	0	0	0	0	0	0
Central banks	0	0	0	0	0		0	0	0	0	0	
General governments	0	0	0	0	0		0	0	0	0	0	
Credit institutions	0	0	0	0	0		0	0	0	0	0	
Other financial corporations	0	0	0	0	0		0	0	0	0	0	
Non-financial corporations	0	0	0	0	0		0	0	0	0	0	
Loans and advances (including at amortised cost and fair value)	827	580	215	200	463	293	737	497	210	191	449	271
Central banks	0	0	0	0	0	0	0	0	0	0	0	0
General governments	2	1	1	1	0	0	2	1	1	1	0	0
Credit institutions	0	0	0	0	0	0	0	0	0	0	0	0
Other financial corporations	0	0	0	0	0	0	0	0	0	0	0	0
Non-financial corporations	293	216	125	118	71	38	257	188	113	105	98	61
of which: small and medium-sized enterprises at amortised cost	274	206	115	109	71		238	177	103	96	96	
Households	532	362	90	81	392	255	478	308	96	85	351	210
DEBT INSTRUMENTS other than HFT	827	580	215	200	463		737	497	210	191	449	
Loan commitments given	4	1	0	0	2	1	3	1	0	0	1	0
QUALITY OF FORBEARANCE ²												
Loans and advances that have been forborne more than twice	0						0					
Non-performing forborne loans and advances that failed to meet the non-performing exit criteria	0						0					

⁽¹⁾ For the definition of forborne exposures please refer to COMMISSION IMPLEMENTING REGULATION (EU) 2015/227 of 9 January 2015, ANNEX V, Part 2-Template related instructions, subtitle 30

⁽²⁾ For the on-balance sheet items, accumulated impairments and accumulated negative changes in fair value due to credit risk are disclosed with a positive sign if they are decreasing assets. Following this sign convention, information is disclosed with the opposite sign of what is reported according to the FINREP framework (templates F 18.00 / F 19.00), which follows a sign convention based on a credit/debit convention, as explained in Annex V, Part 1 paragraphs 9 and 10 of Regulation (EU) No 680/2014 - ITS on Supervisory reporting. However, for the off-balance sheet instruments, the same item ("Accumulated impairment, accumulated changes in fair value due to credit risk and provisions") is disclosed consistently with the FINREP sign convention. This is because, based on this sign convention, the provisions on off-balance sheet commitments are generally reported with a positive sign.

2021 EU-wide Transparency Exercise

Forborne exposures

Ibercaja Banco, S.A.

	As of 31/03/2021						As of 30/06/2021					
	Gross carrying amount of exposures with forbearance measures		Accumulated impairment, accumulated changes in fair value due to credit risk and provisions for exposures with forbearance measures ²		Collateral and financial guarantees received on exposures with forbearance measures		Gross carrying amount of exposures with forbearance measures		Accumulated impairment, accumulated changes in fair value due to credit risk and provisions for exposures with forbearance measures ²		Collateral and financial guarantees received on exposures with forbearance measures	
		Of which non-performing exposures with forbearance measures		Of which non-performing exposures with forbearance measures		Of which collateral and financial guarantees received on non-performing exposures with forbearance measures		Of which non-performing exposures with forbearance measures		Of which non-performing exposures with forbearance measures		Of which collateral and financial guarantees received on non-performing exposures with forbearance measures
(mln EUR)												
Cash balances at central banks and other demand deposits	0	0	0	0	0	0	0	0	0	0	0	0
Debt securities (including at amortised cost and fair value)	0	0	0	0	0	0	0	0	0	0	0	0
Central banks	0	0	0	0	0		0	0	0	0	0	
General governments	0	0	0	0	0		0	0	0	0	0	
Credit institutions	0	0	0	0	0		0	0	0	0	0	
Other financial corporations	0	0	0	0	0		0	0	0	0	0	
Non-financial corporations	0	0	0	0	0		0	0	0	0	0	
Loans and advances (including at amortised cost and fair value)	691	485	199	183	423	267	647	451	188	173	394	248
Central banks	0	0	0	0	0	0	0	0	0	0	0	0
General governments	2	1	1	1	0	0	1	1	1	1	0	0
Credit institutions	0	0	0	0	0	0	0	0	0	0	0	0
Other financial corporations	0	0	0	0	0	0	0	0	0	0	0	0
Non-financial corporations	237	181	107	100	91	58	219	169	102	96	77	54
of which: small and medium-sized enterprises at amortised cost	223	172	99	93	89		206	161	95	89	75	
Households	452	304	92	82	332	208	428	282	85	76	316	193
DEBT INSTRUMENTS other than HFT	691	485	199	183	423		647	451	188	173	394	
Loan commitments given	3	1	0	0	1	0	4	2	0	0	1	1
QUALITY OF FORBEARANCE ²												
Loans and advances that have been forborne more than twice	0						0					
Non-performing forborne loans and advances that failed to meet the non-performing exit criteria	0						0					

(1) For the definition of forborne exposures please refer to COMMISSION IMPLEMENTING REGULATION (EU) 2015/227 of 9 January 2015, ANNEX V, Part 2-Template related instructions, subtitle 30

(2) For the on-balance sheet items, accumulated impairments and accumulated negative changes in fair value due to credit risk are disclosed with a positive sign if they are decreasing assets. Following this sign convention, information is disclosed with the opposite sign of what is reported according to the FINREP framework (templates F 18.00 / F 19.00), which follows a sign convention based on a credit/debit convention, as explained in Annex V, Part 1 paragraphs 9 and 10 of Regulation (EU) No 680/2014 - ITS on Supervisory reporting. However, for the off-balance sheet instruments, the same item ('Accumulated impairment, accumulated changes in fair value due to credit risk and provisions') is disclosed consistently with the FINREP sign convention. This is because, based on this sign convention, the provisions on off-balance sheet commitments are generally reported with a positive sign.

2021 EU-wide Transparency Exercise
Breakdown of loans and advances to non-financial corporations other than held for trading
Ibercaja Banco, S.A.

(mn EUR)	As of 30/09/2020						As of 31/12/2020						As of 31/03/2021						As of 30/09/2021					
	Gross carrying amount		Of which: non-perform		Of which loans and advances subject to impairment		Gross carrying amount		Of which: non-perform		Of which loans and advances subject to impairment		Gross carrying amount		Of which: non-perform		Of which loans and advances subject to impairment		Gross carrying amount		Of which: non-perform		Of which loans and advances subject to impairment	
		of which: defaulted			Accumulated impairment ¹	Accumulated negative changes in fair value due to credit risk on non-performing exposures ¹		of which: defaulted			Accumulated impairment ¹	Accumulated negative changes in fair value due to credit risk on non-performing exposures ¹		of which: defaulted			Accumulated impairment ¹	Accumulated negative changes in fair value due to credit risk on non-performing exposures ¹		of which: defaulted			Accumulated impairment ¹	Accumulated negative changes in fair value due to credit risk on non-performing exposures ¹
A Agriculture, forestry and fishing	376	12	12	376	12	0	362	11	11	361	11	0	361	13	13	360	11	0	360	11	11	358	9	0
B Mining and quarrying	17	1	1	17	1	0	17	1	1	17	1	0	16	1	1	16	0	0	16	1	1	16	0	0
C Manufacturing	1,225	53	53	1,223	45	0	1,315	44	44	1,315	44	0	1,449	46	46	1,449	41	0	1,381	43	43	1,381	45	0
D Electricity, gas, steam and air conditioning supply	148	0	0	148	2	0	110	0	0	110	2	0	124	0	0	124	2	0	148	0	0	148	2	0
E Water supply	45	1	1	45	1	0	37	1	1	37	1	0	53	1	1	53	1	0	52	1	1	52	1	0
F Construction	1,532	149	149	1,533	89	0	1,488	112	112	1,488	63	0	1,592	114	114	1,592	63	0	1,550	104	103	1,550	98	0
G Wholesale and retail trade	1,404	75	75	1,404	61	0	1,481	75	75	1,480	67	1	1,619	74	74	1,619	64	0	1,525	71	71	1,525	67	0
H Transport and storage	339	20	20	339	17	0	304	17	17	304	18	0	372	16	16	372	16	0	365	16	16	365	15	0
I Accommodation and food service activities	229	23	23	229	28	0	226	25	25	226	48	0	220	27	27	220	48	0	212	28	28	212	16	0
J Information and communication	130	12	12	130	8	0	117	9	9	117	7	0	115	9	9	115	7	0	135	9	9	135	8	0
K Financial and insurance activities	91	2	2	91	3	0	192	2	2	192	4	0	325	3	3	325	5	0	321	3	3	321	5	0
L Real estate activities	415	37	37	415	29	0	424	38	38	424	29	0	446	40	40	446	28	0	450	33	19	450	26	0
M Professional, scientific and technical activities	458	31	31	458	66	0	304	33	33	304	20	0	318	33	33	318	32	0	323	31	31	323	36	0
N Administrative and support service activities	226	13	13	226	11	0	196	8	8	196	9	0	213	8	8	213	8	0	221	8	8	221	7	0
O Public administration and defence, compulsory social security	0	0	0	0	0	0	50	0	0	50	0	0	50	0	0	50	0	0	50	0	0	50	0	0
P Education	28	2	2	28	1	0	28	1	1	28	1	0	27	1	1	27	1	0	26	1	1	26	1	0
Q Human health services and social work activities	84	16	16	84	11	0	87	16	16	87	12	0	88	14	14	88	16	0	84	15	15	84	16	0
R Arts, entertainment and recreation	47	9	9	46	8	1	43	9	9	42	8	1	43	9	9	42	8	1	42	10	10	41	8	1
S Other services	56	3	3	55	2	1	116	1	1	116	2	0	57	2	2	57	1	0	49	2	2	49	1	0
Loans and advances	6,901	461	461	6,897	386	2	6,938	403	389	6,924	347	2	7,442	412	398	7,439	351	1	7,011	386	371	7,308	321	1

⁽¹⁾ The items 'accumulated impairment' and 'accumulated negative changes in fair value due to credit risk on non-performing exposures' are disclosed with a positive sign if they are decreasing an asset. Following this sign convention, information is disclosed with the opposite sign of what is reported according to the FINREP framework (template F 06.01), which follows a sign convention based on a credit/debit convention, as explained in Annex V, Part 1 paragraphs 9 and 10 of Regulation (EU) No 680/2014 - ITS on Supervisory reporting.

2021 EU-wide Transparency Exercise
Information on loans and advances subject to legislative and non-legislative moratoria and public guarantee schemes in accordance with EBA Guidelines
EBA/GL/2020/02
Ibercaja Banco, S.A.

(mln EUR)	As of 30/09/2020														As of 31/12/2020																	
	Gross carrying amount						Accumulated impairment, accumulated negative changes in fair value due to credit risk								Maximum amount of the guarantee that can be considered	Gross carrying amount						Accumulated impairment, accumulated negative changes in fair value due to credit risk								Maximum amount of the guarantee that can be considered	Gross carrying amount	
	Performing			Non-performing			Performing			Non-performing			Performing			Non-performing			Performing			Non-performing										
	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days					
Loans and advances subject to active EBA-compliant moratoria	205	207	17	55	6	7	0	3	2	1	2	1	1	0	0	1	266	268	19	93	10	8	9	6	5	1	4	1	1	0	0	
of which: Households	292	295	17	53	7	6	0	3	2	1	2	1	1	0	0	1	331	332	19	77	6	7	7	5	4	1	3	1	1	0	0	
of which: Collateralised by residential immovable property	273	266	15	49	7	6	0	3	2	1	2	1	1	0	0	1	309	301	17	74	8	7	7	5	4	1	3	1	1	0	0	
of which: Non-financial corporations	11	12	1	2	0	0	0	0	0	0	0	0	0	0	0	0	36	34	0	17	2	1	2	1	1	0	1	0	0	0	0	
of which: Small and Medium-sized Enterprises	11	12	1	2	0	0	0	0	0	0	0	0	0	0	0	0	35	35	0	16	2	1	2	1	1	0	1	0	0	0	0	
of which: Collateralised by commercial immovable property	12	12	1	2	0	0	0	0	0	0	0	0	0	0	0	0	32	30	0	16	2	1	2	1	1	0	1	0	0	0	0	

(mln EUR)	As of 30/09/2020																As of 31/12/2020																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																				
	Gross carrying amount						Accumulated impairment, accumulated negative changes in fair value due to credit risk									Maximum amount of the guarantee that can be considered	Gross carrying amount						Accumulated impairment, accumulated negative changes in fair value due to credit risk									Maximum amount of the guarantee that can be considered	Gross carrying amount																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																				
	Performing			Non-performing			Performing			Non-performing			Performing			Non-performing			Performing			Non-performing																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																															
	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)

(mln EUR)	As of 30/09/2020																	As of 31/12/2020																																																																																																																																																					
	Gross carrying amount							Accumulated impairment, accumulated negative changes in fair value due to credit risk							Maximum amount of the guarantee that can be considered	Gross carrying amount							Accumulated impairment, accumulated negative changes in fair value due to credit risk							Maximum amount of the guarantee that can be considered	Gross carrying amount																																																																																																																																								
	Performing		Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Non-performing		Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures	Of which: instruments likely to pay that are not past-due or past-due <= 90 days	Of which: exposures with reference measures

[illegible]